Methods and Compositions for Providing Protective Immunity in the Elderly
AssigneeVaxInnate Corporation
InventorsDavid Taylor, Alan Shaw, Lynda Tussey, Robert Becker
Life of this patent
Estimating the term…
Abstract
Compositions that include a flagellin/antigen protein comprising at least a portion of at least one flagellin and at least a portion of at least one antigen and methods of administering these compositions to humans at least 49 years old. The compositions stimulate immune response to the antigen, in particular, a protective immune response to the antigen, in the human, such as an elderly human.
Claims44
A method of stimulating an immune response in a human, comprising the step of administering to the human a composition that includes a fusion protein comprising at least a portion of at least one flagellin and at least a portion of at least one antigen, wherein the fusion protein is administered to the human in a dose greater than about a 0.5 μg dose and the human is at least 49 years old.
A method of stimulating an immune response in an elderly human population, comprising the step of administering to the human population a composition that includes a fusion protein comprising at least a portion of at least one flagellin and at least a portion of at least one antigen, wherein the seroresponse rate is at least 75%.
A method of stimulating an immune response in an elderly human population, comprising the step of administering to the human population a composition that includes a fusion protein comprising at least a portion of at least one flagellin and at least a portion of at least one antigen, wherein the seroprotection rate is at least 95%.
A method of stimulating an immune response in an elderly human population, comprising the step of administering to the human population a composition that includes a fusion protein comprising at least a portion of at least one flagellin and at least a portion of at least one antigen, wherein the seroconversion rate is at least 50%.
A method of stimulating an immune response in an elderly human population, comprising the step of administering to the human population a composition that includes a fusion protein comprising at least a portion of at least one flagellin and at least a portion of at least one influenza antigen.
A method of stimulating an immune response in a human, comprising the step of administering to the human a composition that includes comprising at least a portion of at least one flagellin and at least a portion of at least one antigen associated with a particle, wherein the human is at least 49 years old.
A method of stimulating an immune response in an elderly human population, comprising the step of administering to the human population a composition comprising at least a portion of at least one flagellin and at least a portion of at least one antigen, wherein the seroresponse rate is at least 75%.
A method of stimulating an immune response in an elderly human population, comprising the step of administering to the human population a composition comprising at least a portion of at least one flagellin and at least a portion of at least one antigen, wherein the seroprotection rate is at least 95%.
A method of stimulating an immune response in an elderly human population, comprising the step of administering to the human population a composition comprising at least a portion of at least one flagellin and at least a portion of at least one antigen, wherein the seroconversion rate is at least 50%.
A method of stimulating an immune response in an elderly human population, comprising the step of administering to the human population a composition comprising at least a portion of at least one flagellin and at least a portion of at least one influenza antigen.
The nucleic acid sequence as set forth in Seq ID 2.
The nucleic acid sequence as set forth in Seq ID 4.
The nucleic acid sequence as set forth in Seq ID 6.
The polypeptide sequence as set forth in Seq ID 3.
The polypeptide sequence as set forth in Seq ID 5.
The polypeptide sequence as set forth in Seq ID 7.
A method of stimulating an immune response in an elderly human population, comprising the step of administering to the human population a composition comprising at least 3 μg of SEQ ID No. 1, wherein the immune response produced by administration of the composition in an elderly population meets or exceeds one of the following criteria:
- a seroconversion rate of greater than 50%, greater than 60%, greater than 70%, greater than 80%, greater than 90%, greater than 95% or greater than 99%.
- a seroprotection rate of greater than 50%, greater than 60%, greater than 70%, greater than 80%, greater than 90%, greater than 95% or greater than 99%.
- an average four-fold or greater increase in neutralizing antibody titer at post vaccination.
Dependencies are inferred from the claim text.